Mr. Canann has over 20 years of operating and investing experience with healthcare companies. At NaviMed, he sits on the firm’s Investment Committee and is responsible for portfolio and firm operations. Prior to co-founding NaviMed Capital, he focused on growth stage healthcare investments at The Carlyle Group for seven years. Prior to joining The Carlyle Group, he held various strategic planning and global marketing management positions at Medtronic, where he managed global launch planning efforts to achieve the company’s sales targets within a $5 billion product category and Edwards Lifesciences (formerly Baxter International). He was also a CPA in the Boston office of Price Waterhouse.
Mr. Canann currently serves on the Board of Directors of Lucent Health Solutions and previously served on the Board of Directors of several portfolio companies of The Carlyle Group including Carefx (sold to Harris Corporation), Elenza and Primary Health (sold to PacificSource Health Plans). In addition, he has been actively involved in a number of Carlyle’s other successful healthcare investments including Endius (sold to Zimmer) and AqueSys. Mr. Canann served from 2008 to 2013 on the Cleveland Clinic Innovation Advisory Board.
Mr. Canann holds an MS and a BS from Brigham Young University and an MBA from Harvard Business School.